



# House of Representatives *State of Utah*

UTAH STATE CAPITOL COMPLEX • 350 STATE CAPITOL  
P.O. BOX 145030 • SALT LAKE CITY, UTAH 84114-5030 • (801) 538-1029

February 15, 2008

Mr. Speaker:

The Health and Human Services Committee reports a favorable recommendation on **H.B. 361**, ANTI-SEIZURE DRUG NOTIFICATION, by Representative E. Hutchings, with the following amendments:

1. *Page 3, Lines 80 through 89:*

- 80        (7) (a) For purposes of Subsection (7) ~~{(b)}~~ , "substitutes" means to substitute:  
81        (i) a generic drug for another generic drug;  
82        (ii) a generic drug for a nongeneric drug;  
83        (iii) a nongeneric drug for another nongeneric drug; or  
84        (iv) a nongeneric drug for a generic drug.  
85        (b) A prescribing practitioner who makes a finding under Subsection (5)(a) for  
a patient with a seizure disorder shall indicate a prohibition on substitution of a drug  
product equivalent in the manner provided in Subsections (5)(a) or (b).  
      (c) Except as provided in Subsection (7) ~~{(c)}~~ (d) , a pharmacist or  
pharmacy intern who cannot dispense the prescribed drug as written, and who needs  
to substitute  
86        ~~{substitutes}~~ a drug product equivalent for ~~{an epilepsy}~~ the drug  
prescribed to ~~{a}~~ the patient to treat or  
87        prevent seizures shall notify the prescribing practitioner prior to the substitution.  
88        ~~{(c)}~~ (d) Notification under Subsection (7) ~~{(b)}~~ (c) is not required  
if the drug product equivalent is  
89        paid for in whole or in part by Medicaid.

Respectfully,

Paul Ray  
Committee Chair

Voting: 6-0-2

3 HB0361.HC1.WPD 2/15/08 10:29 am markandrews/MDA CJD/MDA

Bill Number



HB0361

Action Class



H

Action Code



HCRAMD